0306 Early survival benefit of SARS-CoV-2 mRNA vaccination during immune checkpoint inhibitor therapy in cutaneous melanoma & squamous cell carcinoma
Journal of Investigative Dermatology · 2026-08 · 146 (8) · S53
DOI: 10.1016/j.jid.2026.06.337 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Investigative Dermatology, 2026-08. Verfasst von D. Mendez und 3 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Mendez, D., Hill, M., Guzman, N., & Arbesman, J. (2026). 0306 Early survival benefit of SARS-CoV-2 mRNA vaccination during immune checkpoint inhibitor therapy in cutaneous melanoma & squamous cell carcinoma. Journal of Investigative Dermatology, 146(8), S53. https://doi.org/10.1016/j.jid.2026.06.337
Vancouver
Mendez D, Hill M, Guzman N, Arbesman J. 0306 Early survival benefit of SARS-CoV-2 mRNA vaccination during immune checkpoint inhibitor therapy in cutaneous melanoma & squamous cell carcinoma. Journal of Investigative Dermatology. 2026;146(8):S53. doi:10.1016/j.jid.2026.06.337
BibTeX
@article{Mendez2026,
author = {Mendez, D. and Hill, M.A. and Guzman, N. and Arbesman, J.},
title = {0306 Early survival benefit of SARS-CoV-2 mRNA vaccination during immune checkpoint inhibitor therapy in cutaneous melanoma & squamous cell carcinoma},
journal = {Journal of Investigative Dermatology},
year = {2026},
volume = {146},
number = {8},
pages = {S53},
doi = {10.1016/j.jid.2026.06.337}
}
EUVIMED